What are the first-line treatments for migraine prevention?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 9, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

First-Line Treatments for Migraine Prevention

Beta blockers (propranolol 80-240 mg/day or timolol 20-30 mg/day), topiramate (100 mg/day), and candesartan are the recommended first-line medications for migraine prevention. 1, 2

Indications for Preventive Therapy

  • Preventive therapy should be considered for patients who experience two or more migraine attacks per month with disability lasting 3 or more days per month 1, 2
  • Patients who have contraindications to or failure of acute treatments should be evaluated for preventive therapy 1, 2
  • Those using abortive medication more than twice per week should be considered for preventive treatment to avoid medication overuse headache 1, 2
  • Patients with uncommon migraine conditions (hemiplegic migraine, migraine with prolonged aura, or migrainous infarction) are candidates for preventive therapy 1

First-Line Preventive Medications

Beta Blockers

  • Propranolol (80-240 mg/day) and timolol (20-30 mg/day) have strong evidence for efficacy 1, 3
  • Common side effects include dizziness, nausea, fatigue, depression, and insomnia, though these are generally well-tolerated 1
  • Propranolol has demonstrated efficacy in reducing migraine frequency in controlled trials 3

Topiramate

  • Recommended dose is 100 mg/day (typically 50 mg twice daily) 1, 4, 5
  • Clinical trials show topiramate reduces migraine days by approximately two per month 6
  • Most common side effects include paresthesia (51% at 100 mg/day), fatigue, decreased appetite, and cognitive difficulties 4, 5
  • Particularly beneficial for patients concerned about weight gain, as it is often associated with weight loss 5
  • Efficacy has been demonstrated even in chronic migraine with medication overuse 7

Candesartan

  • Emerging evidence supports candesartan as a first-line agent 1
  • Particularly useful for patients with comorbid hypertension 1

Second-Line Preventive Medications

  • Amitriptyline (30-150 mg/day) is recommended as a second-line agent 1

  • May be particularly effective in patients with mixed migraine and tension-type headache 1

  • Common side effects include weight gain, drowsiness, and anticholinergic symptoms 1

  • Flunarizine (not available in the US) is a second-line option where available 1

  • Sodium valproate (800-1500 mg/day) or divalproex sodium (500-1500 mg/day) are second-line options 1

    • These are strictly contraindicated in women of childbearing potential due to teratogenic effects 1
    • Side effects include hair loss, tremor, and weight gain 1

Third-Line Preventive Medications

  • CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) are recommended as third-line agents 1
  • In Europe, these are restricted to patients in whom other preventive medications have failed 1
  • OnabotulinumtoxinA (Botox) is FDA-approved for chronic migraine prevention in adults with 15 or more headache days per month 8

Implementation of Preventive Therapy

  • Start with a low dose and titrate slowly until clinical benefits are achieved or side effects limit further increases 1, 2
  • Allow an adequate trial period of 2-3 months before determining efficacy 1, 2
  • Monitor for medication overuse, which can interfere with preventive treatment 2
  • Use headache diaries to track attack frequency, severity, duration, disability, treatment response, and adverse effects 2

Common Pitfalls to Avoid

  • Failing to recognize medication overuse headache from frequent use of acute medications 2
  • Inadequate duration of preventive trial (less than 2-3 months) 2
  • Starting with too high a dose, leading to poor tolerability and discontinuation 1
  • Not addressing comorbidities that may influence treatment selection (e.g., avoiding valproate in women of childbearing potential) 1

Non-Pharmacological Options

  • Consider neuromodulatory devices, biobehavioral therapy, or acupuncture as adjuncts to medication or as stand-alone treatments when medications are contraindicated 1
  • Limited evidence exists for physical therapy, spinal manipulation, and dietary approaches 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Migraine Prophylaxis Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Topiramate for migraine prevention.

Pharmacotherapy, 2006

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.